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Abstract 
Purpose: To evaluate the effect of bryostatin I on proliferation of pancreatic cancer cells as well as 
tumor growth in mice tumor xenograft model.  
Methods: Activation of NF-κB was evaluated by preparing nuclear material extract using nuclear extract 
kit (Carlsbad, CA, USA) followed by enzyme-linked immunosorbent assay (ELISA). Mice were injected 
with 3 x 105 MIApaCa 2 cells in 100 μL volume of PBS. The animals in the treatment group were 
injected with 50 µg/kg of bryostatin 1 daily for 1 month in the morning whereas those in the untreated 
group received an equal volume of normal saline. 
Results: Treatment of the MIApaCa 2 cells with bryostatin I caused a significant reduction in the activity 
of NF-κB in nucleoplasm (p = 0.0002).  The increase in the concentration of bryostatin I from 10 to 50 
µM reduced MIApaCa 2 cell proliferation from 87 to 26 %. Bryostatin I treatment also led to increase in 
the proportion of cells in M1 phase with subsequent reduction in sub-G1 phase of cell cycle. 
Examination of the cell lysates revealed a higher expression level of cleaved caspase-8 in bryostatin I-
treated MIApaCa 2 cells. Mean tumor diameter in the treatment and untreated groups was 5.34 ± 2.16 
and 19.45 ± 5.71 mm, respectively, after 2 months of treatment (p < 0.0002). The mean weight of the 
tumors in the treatment and untreated groups was 123.67 ± 22.56 and 939.14 ± 213.51 mg, 
respectively, after 2 months of treatment.  
Conclusion: Bryostatin I inhibits growth and proliferation of pancreatic cancer through inhibition of NF-
κB expression, and therefore, needs to be further investigated for therapeutic application in pancreatic 
cancer.                                 
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Pancreatic cancer is one of the most aggressive 
and common causes of deaths caused by cancer 
with a five year survival rate of less than 4 % 
[1,2]. The characteristic features of the 
pancreatic carcinoma cells include high rate of 
proliferation and rapid invasive potential to 
adjacent tissues [3]. Pancreatic cancer because 
of no prominent symptoms is usually detected in 
its advanced stage which is a major hindrance to 
treatment strategies [4]. 
 
It is reported that in the regulation of cellular 
processes including, apoptosis, inflammation, 
and oncogenesis NF-κB has a vital role [5,6]. 
Therefore, suppression of NF-κB expression by 
various strategies has been found to be of great 
therapeutic importance for the treatment of 
cancers [7,8]. Enhanced expression of NF-κB 
was shown to correlate with aggressiveness of 
pancreatic cancer cell metastasis [9,10]. 
Activation of the factors involved in apoptosis has 
a great impact on the inhibition of the cancer cell 
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proliferation and in turn carcinoma treatment [11]. 
NF-κB is found in the cell cytoplasm in its 
inactive form, p50-p65 complex and p65-p105. 
Activation of NF-κB is induced by the 
phosphorylation of IκBα which then results in 
translocation of NF-κB to nucleus. Penetration of 
NF-κB into the nucleus causes expression of the 
genes which initiate various activities such as 
induction of apoptosis and inflammation [12,13]. 
 
Phytochemical investigation of the Bugula 
neritina and marine bryozoa has led to the 
isolation of 20 macrocyclic lactones known as 
bryostatins. Screening of these lactones against 
leukemia cell lines showed that these 
compounds possess potent cytotoxic activities 
[14]. Bryostatin I the most active compound is 
currently in phase II clinical trials for the 
treatment cancers [15-17]. In addition, bryostatin 
I treatment has been shown to promote the 
growth and proliferation of bone marrow 
progenitor cells [17]. Thus, bryostatin I treatment 
has overcome the disadvantages associated with 
the application of dangerous ionizing radiations 
[18]. The present study was aimed to investigate 
the effect of bryostatin I on pancreatic cancer cell 






Bryostatin 1 and dimethyl sulphoxide (DMSO) 
were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). Bryostatin 1 was dissolved in DMSO 
and stored under inert atmosphere at -40 oC.  
 
Cell line and culture 
 
Human pancreatic carcinoma cell line, MIApaCa 
2 was obtained from the American Type Culture 
Collection (Rockville, MD, USA). The cells were 
cultured in RPMI 1640 medium (Nissui 
Pharmaceutical Co., Ltd., Tokyo, Japan) 
containing 10 % heat inactivated fetal bovine 
serum (JRH Biosciences, Lenexa, KS, USA), and 
antibiotics. The cells were maintained in a 




Thirty 8-week old mice, (BALBc nu/nu) were 
obtained from CLEA Japan Incorporated (Tokyo, 
Japan). All experiments involving animals were 
conducted in accordance with the National 
Institute of Health Guide for the Care and Use of 
Laboratory Animals [19]. All animal experiments 
were approved by the Ethics Committee of Wuxi 
No. 2 Hospital Affiliated to Nanjing Medical 
University (protocol no. FGS20131108). The 
mice were acclimatized to the laboratory 
atmosphere one week before the start of actual 
experiment. All the mice were caged and housed 
in the rooms with 12 h light and dark cycle at 25 
oC temperature with free access to food and 
water. All the experiments on animals followed 
the National Institutes of Health criteria for the 
care and use of laboratory animals. The study 
was also approved by the Laboratory Animal 
Care Committee of Sun Yat-sen University 
(Guangzhou, China). 
 
Quantitative analysis of NF-κB activity  
 
MIApaCa 2 cells were treated with 10 - 50 µM of 
bryostatin 1 for 12, 24 and 48 h and then 
analyzed for the expression of NF-κB p65. 
Following incubation, nuclear extract kit 
(Carlsbad, CA, USA) was used to prepare the 
extract of the nuclear material as per the manual 
instructions. The nuclear extract of the cells was 
then analyzed by enzyme-linked immunosorbent 
assay (ELISA) kit (TransAM™ NF-κB; Active 
Motif). For this purpose, 5 μg samples of the 
nuclear material were incubated with 
oligonucleotide containing NF-κB p65-binding 
sequence for a period of 45 min at 30 oC in a 
microwell. The nucleoplasm samples were then 
incubated with rabbit anti-NF-κB p65 antibodies 
(Qiagen, TX, USA) for 45 min at 30 oC, followed 
by peroxidase-conjugated goat anti-rabbit IgG 
(Qiagen, TX, USA) for 45 min at 30 oC. 
Tetramethylbenzidine reaction was used for the 
visualization of peroxidase activity and the 
optimal density was measured at 465 nm. 
 
Cell proliferation assay  
 
The standard 3 (4, 5 dimethylthiazol 2 yl) 2,5 
diphenyltetrazolium bromide assay was used for 
the analysis of inhibition of proliferation in 
pancreatic carcinoma cells. The cells were 
treated with bryostatin 1 at various 
concentrations (10, 20, 30, 40 and 50 μM) for 
various time periods or with DMSO alone as the 
control. The density of the bryostatin 1- and 
DMSO treated cells was compared to determine 
the rate of cell proliferation inhibition by 
bryostatin 1.  
 
Western blot analysis  
 
MIApaCa 2 cells after incubation with bryostatin 
1 were washed with PBS and treated with lysis 
buffer (Beyotime). The concentration of the 
proteins in the cell lysates was measured by 
Bradford method using bovine serum albumin as 
standard. 5 mg samples of the proteins were 
loaded into 10 % SDS-polyacrylamide gels and 
subjected to electrophoresis using constant 
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voltage. The proteins were then transferred onto 
PVDF membranes (Millipore, Bedford, MA, 
USA). The non-specific sites in the membrane 
were blocked by incubation with blocking buffer 
(5 % skim milk in TBS-T) for 3 h at room 
temperature. The membrane was then incubated 
with pro- and cleaved caspase-8, IκB· and 
phosphorylated IκB· monoclonal antibodies 
(Santa Cruz Biotechnology, Inc.) at 4 oC 
overnight. The membranes were washed three 
times with TBS-T and then incubated with a 
secondary antibody (Santa Cruz Biotechnology, 
Inc.) at room temperature for 1 h. The 
immunoreactive bands were visualized using 
enhanced chemiluminescence kits (Pierce 
Biotechnology Inc., Rockford, IL, USA). Blots 
were stained with anti-β-actin or -GAPDH 
antibody (Santa Cruz Biotechnology, Inc.) as an 
internal control for the amounts of target proteins. 
 
Cell cycle analysis 
 
MIApaCa 2 cells were distributed at a density of 
3 x 106 cells per well in 6-well plates at 37 oC and 
incubated with bryostatin 1. After incubation for 
48 h, the cells were washed with PBS, 
resuspended with 200 μL RNase A (1 mg/mL) 
and PI (200 μg/mL) (Beyotime, Haimen, China) 
for staining the DNA content. Following 
incubation for 30 min at room temperature in the 
dark, the cellular DNA was analyzed by 
FACSCalibur flow cytometer. ModFitLT V2.0 
software (both from Becton-Dickinson) was used 
for the analysis of the data. 
 
Preparation of pancreatic xenograft cancer 
model  
 
3 x 105 MIApaCa 2 cells suspended in 100 μl 
volume of PBS were injected into the mice on 
right dorsal side of the body. The animals were 
then randomly divided into the two groups of 15 
animals each (treatment and untreated groups). 
The animals in the treatment group were injected 
50 µg/kg body weight doses of bryostatin 1 dialy 
for 1 month in the morning whereas those in the 
untreated group received equal volume of normal 
saline. Five animals from each of the group were 
sacrificed after 30, 60 and 90 days following 
administration of MIApaCa 2 cells. The tumors 
mass from each of the animal was extracted, 




The results are expressed as mean ± standard 
deviation (SD). For statistical analysis, SPSS 
16.0 software was used. Comparison of the 
results was performed using one-way analysis of 
variance (ANOVA) and Student-Newman-Keuls 
test. Differences were considered statistically 




Effect of bryostatin I on NF-κB activity  
 
Treatment of the MIApaCa 2 cells with bryostatin 
I caused a significant reduction in the activity of 
NF-κB in nucleoplasm compared to untreated 
cells (p = 0.0002, Fig. 1A).  Bryostatin I treatment 
markedly inhibited the activation of IκB in 
MIApaCa 2 cells after 48 h compared to 
untreated cells (Fig. 1B). It was observed that the 
level of activated IκB in bryostatin I treated 
MIApaCa 2 cells was significantly lower than 
those in untreated cells. 
 
 
Figure 1: (A) Effect of bryostatin I on NF-κB p65 expression in MIApaCa-2 cell nuclear extracts; (B) Effect of 
bryostatin I on phosphorylated IκB using western blot analysis 
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Bryostatin I Inhibits proliferation of 
MIApaCa-2 cells 
 
The results from MTT assay revealed that 
bryostatin I exhibited concentration and time 
dependent inhibitory effects on the proliferation 
of MIApaCa-2 cells.  Increase in concentration of 
bryostatin I from 10 to 50 µM reduced the 
percentage of MIApaCa-2 cell proliferation from 
87 to 26 % (Fig. 2). The rate of proliferation in 
MIApaCa-2 cells on treatment with 50 µM 
bryostatin I after 12, 24 and 48 h was found to be 
91.23 ± 6.11, 43.89 ± 3.45 and 26.14 ± 2.67 %, 
respectively (Fig. 2). 
 
Bryostatin I induced apoptosis in MIApaCa-2 
cells 
 
Bryostatin I treatment led to the increase in 
proportion of cells in M1 phase compared to the 
untreated cells (Fig. 3A). However, the proportion 
of cells in sub-G1 phase of cell cycle was 
reduced by bryostatin I treatment. Examination of 
the cell lysates revealed higher expression level 
of cleaved caspase-8 in the bryostatin I treated 
MIApaCa-2 cells compared to untreated cells 
(Fig. 3B). 
 
Bryostatin I treatment inhibits tumor growth 
in vivo 
 
Comparison of the tumor growth in bryostatin I 
treated and untreated mice after 2 months 
revealed a significantly lower tumor volume in 
treatment group than in untreated group (Fig. 
4a). The average tumor volumes in the treatment 
and untreated groups were found to be 5.34 ± 
2.16 and 19.45 ± 5.71 mm, respectively after 2 
months of the treatment period (p < 0.0002) (Fig. 
4A). The average weight of the tumors in the 
treatment and untreated groups were 123.67 ± 
22.56 and 939.14 ± 213.51 mg, respectively after 
2 months of the treatment (Fig. 4B). 
 
 
Figure 2: Inhibition of MIApaCa-2 cell viability by bryostatin I after treatment for 12, 24 and 48 h. The cells were 
incubated with 10 to 50 µM concentrations of bryostatin I for 12, 24 and 48 h and then analyzed by MTT assay 
 
 
Figure 3: (A) Bryostatin I treatment increases the proportion of cells in the M1 phase with subsequent reduction 
in the sub-G1 phase of cell cycle; (B) Bryostatin I treatment enhanced the expression of pro-caspase-8 in 
MIApaCa-2 cells 
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Figure 4: (A) Bryostatin I inhibited tumor growth in the MIApaCa-2 cell tumor xenograft model; (B) tumor weights 




The present study investigates the effect of 
bryostatin I on proliferation of pancreatic cancer 
cells as well as tumor growth in mice tumor 
xenograft model. The study revealed that 
bryostatin I treatment results apoptosis in 
pancreatic carcinoma cells and inhibits growth of 
tumor in vivo by preventing the expression of NF-
κB. The genes associated with the expression of 
proteins involved in the cellular processes, 
including apoptosis and inflammation are 
regulated by NF-κB expression. It is known that 
activation of NF-κB is inhibited during the 
process of inflammation [20,21]. The 
chemotherapeutic inhibition of NF-κB expression 
prevents proliferation, invasion and metastasis of 
cells in various types of cancers [22-24]. 
Although, a number of agents have been 
identified which play an important role in the 
inhibition of NF-κB expression. However, most of 
these agents induce harmful side effects [25]. 
Therefore, the discovery of the molecules which 
can inhibit the expression of NF-κB without side 
effect is highly desired. Our results from the 
current study revealed that bryostatin I treatment 
inhibited the expression of NF-κB in the 
pancreatic carcinoma cells. The level of activated 
IκB in MIApaCa 2 cells was reduced markedly on 
treatment with bryostatin I. Inhibition of 
carcinoma cell proliferation by the use of various 
agents plays important value in the treatment of 
cancer. The present study revealed that 
bryostatin I treatment caused a significant 
inhibition in the rate of proliferation in pancreatic 
carcinoma cells. Bryostatin I treatment in 
pancreatic cells resulted cell cycle arrest by 
increasing proportion of cells in M1 phase and 
subsequent reduction in sub-G1 phase of cell 
cycle. Western blot analysis showed significantly 
higher expression level of cleaved caspase-8 in 
the bryostatin I treated Panc-1 cells compared to 
untreated cells. Thus, bryostatin I induced 
apoptosis in pancreatic carcinoma cells through 
caspase-dependent pathway. Comparison of the 
tumor growth in bryostatin I treated and 
untreated mice after 2 months revealed a 
significantly lower tumor volume in treatment 




The findings of this study indicate that bryostatin 
I induces apoptosis in pancreatic carcinoma cells 
and inhibits tumor growth in vivo through down-
regulation of NF-κB expression. Therefore, 
bryostatin I may be of therapeutic value for the 
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